Condition
Beta Thalassemia Major Anemia
Total Trials
5
Recruiting
1
Active
1
Completed
2
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Low Risk
Score: 17/100
Termination Rate
0.0%
0 terminated out of 5 trials
Success Rate
100.0%
+13.5% vs benchmark
Late-Stage Pipeline
40%
2 trials in Phase 3/4
Results Transparency
50%
1 of 2 completed with results
Key Signals
1 with results100% success
Data Visualizations
Phase Distribution
5Total
Not Applicable (2)
P 2 (1)
P 4 (2)
Trial Status
Unknown2
Completed2
Recruiting1
Trial Success Rate
100.0%
Benchmark: 86.5%
Based on 2 completed trials
Clinical Trials (5)
Showing 5 of 5 trials
NCT05693909Phase 2RecruitingPrimary
A Trial Testing SP-420 in Subjects With Transfusion-dependent β-thalassemia or Low-risk Myelodysplastic Syndromes
NCT03591575Phase 4CompletedPrimary
Safety and Efficacy of Early Treatment With Deferiprone in Infants and Young Children
NCT04962984Not ApplicableUnknownPrimary
Thrombin Generation in Beta-thalassemia Major
NCT03948737Not ApplicableCompletedPrimary
The Effect of Alpha-tocopherol in Hemolysis and Oxidative Stress Marker on the Red Cell Membrane Beta-thalassemia Major
NCT02984475Phase 4UnknownPrimary
The Potential Hepatoprotective Effect of Metformin in Patients With Beta Thalassemia Major
Showing all 5 trials